Novo Nordisk AS
NOV
Company Profile
Business description
With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Contact
Novo Alle 1
Bagsvaerd2880
DNKT: +45 44448888
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2025
Employees
77,406
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,770.90 | 4.10 | -0.05% |
| CAC 40 | 7,742.24 | 57.56 | 0.75% |
| DAX 40 | 23,699.12 | 182.89 | 0.78% |
| Dow JONES (US) | 42,515.09 | 317.30 | 0.75% |
| FTSE 100 | 8,875.22 | 24.59 | 0.28% |
| HKSE | 24,028.83 | 32.16 | -0.13% |
| NASDAQ | 19,701.21 | 294.39 | 1.52% |
| Nikkei 225 | 38,503.49 | 192.16 | 0.50% |
| NZX 50 Index | 12,655.40 | 34.73 | -0.27% |
| S&P 500 | 6,033.11 | 56.14 | 0.94% |
| S&P/ASX 200 | 8,539.90 | 8.50 | -0.10% |
| SSE Composite Index | 3,382.14 | 6.59 | -0.19% |